mRNA-1273新冠疫苗在健康日本成人中的1/2期随机安慰剂对照研究:中期报告
这项在日本两个中心开展的1/2期随机观察者盲法安慰剂对照试验,纳入200名≥20岁健康日本成人,按年龄分层后随机接受两剂100 μg mRNA-1273或安慰剂(间隔28天)。mRNA-1273组 solicited 不良事件发生率为96%(144/150),安慰剂组为38%(19/50);第57天bAb几何平均倍数上升1009(95%CI 865-1177),nAb为21.7(19.8-23.8),bAb和nAb血清转化率均为100%(97.5-100)。结论认为两剂100 μg mRNA-1273间隔28天给药安全性可接受,并诱导显著的抗SARS-CoV-2免疫应答。
要点
- mRNA-1273组 solicited 不良事件发生率96%(144/150),安慰剂组38%(19/50)。
- 第57天bAb几何平均倍数上升1009(95%CI 865-1177),nAb为21.7(19.8-23.8)。
- 第57天bAb和nAb血清转化率均为100%(95%CI 97.5-100)。
核心结论
- 两剂100 μg mRNA-1273间隔28天给药在≥20岁日本人群中安全性可接受,并诱导显著的抗SARS-CoV-2免疫应答。
研究设计与样本
- 1/2期随机观察者盲法安慰剂对照试验,在日本两个中心开展,纳入≥20岁健康成人200名。
- 参与者按年龄(<65岁/≥65岁)分层,随机接受两剂100 μg mRNA-1273或安慰剂,间隔28天肌肉注射。
- mRNA-1273组150名(<65岁100名,≥65岁50名),安慰剂组50名(<65岁40名,≥65岁10名)。
- 主要结局为安全性和抗SARS-CoV-2刺突蛋白结合抗体(bAb)水平,次要结局为SARS-CoV-2中和抗体(nAb)应答。
主要发现
- mRNA-1273组 solicited 不良事件发生率96%(144/150),安慰剂组38%(19/50)。
- mRNA-1273组最常见 solicited 不良事件为注射部位疼痛、肌痛和疲劳,各年龄组一致。
- 第57天mRNA-1273组(n=147)bAb几何平均倍数上升1009(95%CI 865-1177),nAb为21.7(95%CI 19.8-23.8)。
- 第57天bAb和nAb血清转化率均为100%(95%CI 97.5-100);安慰剂组(n=49)无此类应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The mRNA vaccine, mRNA-1273/TAK-919, encodes the prefusion-stabilised spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report interim results of the first study evaluating safety and immunogenicity of mRNA-1273 in healthy Japanese participants. METHODS: This phase 1/2, randomised, observer-blind, placebo-controlled trial, conducted in Japan (two sites), enrolled healthy adults aged ≥ 20 years with no prior exposure to investigational coronavirus vaccines/treatments, and no known history/risk of SARS-CoV-2 infection. Participants were stratified by age (< 65/≥ 65 years) and randomised to receive two doses of 100 μg mRNA-1273 or placebo administered as intramuscular injections 28 days apart. Primary outcomes were safety and immunogenicity assessed by anti-SARS-CoV-2-spike protein-binding antibody level (bAb). A secondary outcome was SARS-CoV-2 neutralising antibody (nAb) response. RESULTS: Participants were enrolled between 21 January and 3 February 2021, and 200 were randomised: mRNA-1273, n = 150 (< 65 years, n = 100; ≥ 65 years, n = 50); placebo, n = 50 (< 65 years, n = 40; ≥ 65 years, n = 10). Solicited adverse events (AEs) through 7 days after each vaccination occurred in 144/150 (96%) and 19/50 (38%) participants in the mRNA-1273 and placebo arms, respectively. In the mRNA-1273 arm, injection-site pain, myalgia and fatigue were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with mRNA-1273 (n = 147) with a bAb geometric mean fold rise (95% confidence interval [CI]) from baseline of 1009 (865, 1177) and a nAb of 21.7 (19.8, 23.8) at day 57. Seroconversion rates (95% CI) for bAb and nAb were both 100% (97.5, 100) at day 57. No such response occurred with placebo (n = 49). CONCLUSION: Two doses of 100 μg mRNA-1273 given 28 days apart demonstrated an acceptable safety profile and induced significant anti-SARS-CoV-2 immune responses in a Japanese population aged ≥ 20 years. FUNDING: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). CLINICALTRIALS: gov: NCT04677660.
引用
- Masuda T, Murakami K, Sugiura K, et al. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. Vaccine. 2022. PMID: 35177302. doi:10.1016/j.vaccine.2022.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。